The World Health Organization (WHO) 2023 Global tuberculosis (TB) report underscores a significant worldwide recovery in the scale-up of TB diagnosis and treatment services in 2022. It shows an encouraging trend starting to reverse the detrimental effects of COVID- 19 disruptions on TB services.
Featuring data from 192 countries and areas, the report shows that 7.5 million people were diagnosed with TB in 2022, making it the highest figure recorded since WHO began global TB monitoring in 1995.
The increase is attributed to good recovery in access to and provision of health services in many countries. India, Indonesia and the Philippines, which together accounted for over 60% of the global reductions in the number of people newly diagnosed with TB in 2020 and 2021, all recovered to beyond 2019 levels in 2022.
“For millennia, our ancestors suffered and died with tuberculosis, without knowing what it was, what caused it, or how to stop it,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Today, we have knowledge and tools they could only have dreamed of. We have political commitment, and we have an opportunity that no generation in the history of humanity has had: the opportunity to write the final chapter in the story of TB.”
Globally, an estimated 10.6 million people fell ill with TB in 2022, up from 10.3 million in 2021. Geographically, in 2022, most people who developed TB were in the WHO Regions of South-East Asia (46%), Africa (23%) and the Western Pacific (18%), with smaller proportions in the Eastern Mediterranean (8.1%), the Americas (3.1%) and Europe (2.2%).
The total number of TB-related deaths (including those among people with HIV) was 1.3 million in 2022, down from 1.4 million in 2021. However, during the 2020-2022 period, COVID-19 disruptions resulted in nearly half a million more deaths from TB. TB continues to be the leading killer among people with HIV.
Multidrug-resistant TB (MDR-TB) remains a public health crisis. While an estimated 410 000 people developed multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) in 2022, only about two in five people accessed treatment.
There is some progress in the development of new TB diagnostics, drugs and vaccines. However, this is constrained by the overall level of investment in these areas.
